BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/14/2025 5:49:34 AM | Browse: 78 | Download: 396
 |
Received |
|
2025-05-15 05:55 |
|
Peer-Review Started |
|
2025-05-15 05:56 |
|
First Decision by Editorial Office Director |
|
2025-05-19 18:06 |
|
Return for Revision |
|
2025-05-20 23:56 |
|
Revised |
|
2025-05-29 02:13 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-07-07 02:39 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-07-07 07:19 |
|
Articles in Press |
|
2025-07-07 07:19 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-08-01 07:50 |
|
Publish the Manuscript Online |
|
2025-08-14 05:49 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Cost-effectiveness analysis of pancreatic enzyme replacement therapy in patients with pancreatic exocrine insufficiency in China
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hansoo Kim, Joshua Byrnes, Kui-Rong Jiang, Zhuan Liao, Arun Jones, Kyoo Kim, Dafni Fragkogianni and Keith J Roberts |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Arun Jones, Health Economics Group, Griffith University, 1 Parklands Dr, Gold Coast QLD4215, Queensland, Australia. arun.jones@griffith.edu.au |
| Key Words |
Pancreatic exocrine insufficiency; Pancreatic enzyme replacement therapy; Cost-effectiveness analysis; National essential medicine list; China |
| Core Tip |
Pancreatic enzyme replacement therapy (PERT) is a first-line treatment for pancreatic exocrine insufficiency (PEI). In China, PERT is not yet listed on the national essential medicine list, which is often a pre-requisite for patients in China to gain access to life-saving treatments. Chinese health policy has an increased emphasis on cost-effectiveness analysis as a prerequisite for drug reimbursement. This analysis undertakes a cost-effectiveness analysis on PERT for the treatment of PEI from a Chinese societal perspective, finding that PERT is cost-effective for the treatment of PEI in China. |
| Publish Date |
2025-08-14 05:49 |
| Citation |
Kim H, Byrnes J, Jiang KR, Liao Z, Jones A, Kim K, Fragkogianni D, Roberts KJ. Cost-effectiveness analysis of pancreatic enzyme replacement therapy in patients with pancreatic exocrine insufficiency in China. World J Gastrointest Oncol 2025; 17(8): 109544 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i8/109544.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i8.109544 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
